Status:
COMPLETED
In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
Lead Sponsor:
University of Sao Paulo General Hospital
Conditions:
Myelomeningocele
Terbutaline Adverse Reaction
Eligibility:
FEMALE
18-40 years
Brief Summary
Myelomeningocele is a malformation with high incidence, and it consists in a neural tube defect. Fetal intrauterine surgery is an alternative for correction, and it improves the prognosis of the fetus...
Detailed Description
The objective of the study was to evaluate maternal blood gas alterations among cases that used atosiban tocolytic agent and cases with terbutaline in in utero repair of myelomeningocele. It consists ...
Eligibility Criteria
Inclusion
- Pregnant women over 18 years
- Single fetus pregnancy
- Fetus with myelomeningocele
- Gestational age from 19 to 26
- Fetus with normal karyotype
Exclusion
- Multiple pregnancy
- Fetal abnormality not related to myelomeningocele
- Kyphosis greater than or equal to 30 degrees
- Placenta previa
- Maternal disease that increases the risk of pregnancy (insulin-dependent DM, hypertension poorly controlled)
- History of incompetent cervix
- Carrier of HIV, hepatitis B or hepatitis C
- Maternal-fetal isoimmunization
- Uterine Alteration
- Obesity (IMC greater than 30)
Key Trial Info
Start Date :
October 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04468568
Start Date
October 1 2017
End Date
April 1 2022
Last Update
June 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil